At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Verseon bets physics can take drug design beyond AI’s training data
Bay Area-based pharmaceutical company Verseon has been a quiet pioneer in computational drug design since 2002, predating the widespread emergence…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant paradigm shift is underway in small-molecule drug discovery, as a pioneering collaboration between Ginkgo Datapoints, Tangible Scientific, and…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
A GLP-1 bone study shows why matching matters in real-world evidence
The burgeoning field of real-world evidence (RWE) is transforming how medical professionals and regulators understand the long-term effects of therapeutics,…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
Navigating the New Frontier: American Biotech’s Strategic Imperatives Amidst Global Competition and Shifting Investment Tides
For several years, the landscape for American biotechnology firms has grown increasingly challenging, with success becoming a more elusive commodity.…
Read More
Arrowfly Emerges as the New Corporate Identity for WTWH Media, Signaling Strategic Expansion and Market Consolidation
Cleveland, Ohio – In a significant corporate development signaling a strategic evolution and a unified market approach, WTWH Media, the…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
ADA Conference Marked by Landmark GLP-1 Trial Results Amidst Unprecedented Scientific Dissent and Police Intervention
The annual national conference of the American Diabetes Association (ADA) this week served as a dual stage: a vibrant forum…
Read MoreYOU MAY HAVE MISSED
